$CLRB
Cellectar Biosciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000141057823000875 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.986M $2.051M
YoY Change -32.39% -8.96%
% of Gross Profit
Research & Development $6.308M $6.654M
YoY Change 40.23% 71.19%
% of Gross Profit
Depreciation & Amortization $38.65K $42.56K
YoY Change 14.01% -1.98%
% of Gross Profit
Operating Expenses $6.308M $6.654M
YoY Change 40.23% 71.19%
Operating Profit -$8.294M -$8.705M
YoY Change 11.55% 41.77%
Interest Expense $72.78K $124.0K
YoY Change 15030.98% 28745.12%
% of Operating Profit
Other Income/Expense, Net $72.78K $124.0K
YoY Change 15030.98% 28745.12%
Pretax Income -$8.221M -$8.581M
YoY Change 10.57% 39.76%
Income Tax
% Of Pretax Income
Net Earnings -$8.221M -$8.581M
YoY Change 10.57% 39.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.73 -$0.76
Diluted Earnings Per Share -$0.73 -$0.76
COMMON SHARES
Basic Shares Outstanding 9.741M 9.741M
Diluted Shares Outstanding 11.26M 11.26M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.153M $12.68M
YoY Change -79.23% -58.6%
Cash & Equivalents $5.153M $12.68M
Short-Term Investments
Other Short-Term Assets $456.7K $1.164M
YoY Change -4.79% 53.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.610M $13.85M
YoY Change -77.81% -55.9%
LONG-TERM ASSETS
Property, Plant & Equipment $337.4K $376.1K
YoY Change -7.51% 13.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $6.214K
YoY Change -92.35% -92.35%
Total Long-Term Assets $899.5K $992.0K
YoY Change 48.15% 66.55%
TOTAL ASSETS
Total Short-Term Assets $5.610M $13.85M
Total Long-Term Assets $899.5K $992.0K
Total Assets $6.509M $14.84M
YoY Change -74.86% -53.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.392M $6.905M
YoY Change 17.01% 53.04%
Accrued Expenses $53.64K $51.11K
YoY Change -62.71% -63.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.445M $6.956M
YoY Change 14.97% 49.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $530.9K $548.3K
YoY Change 475.71% 322.74%
Total Long-Term Liabilities $530.9K $548.3K
YoY Change 475.71% 322.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.445M $6.956M
Total Long-Term Liabilities $530.9K $548.3K
Total Liabilities $6.976M $7.504M
YoY Change 22.42% 56.95%
SHAREHOLDERS EQUITY
Retained Earnings -$196.3M
YoY Change 19.35%
Common Stock $97.00 $97.00
YoY Change 59.02% -84.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$467.0K $7.334M
YoY Change
Total Liabilities & Shareholders Equity $6.509M $14.84M
YoY Change -74.86% -53.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$8.221M -$8.581M
YoY Change 10.57% 39.76%
Depreciation, Depletion And Amortization $38.65K $42.56K
YoY Change 14.01% -1.98%
Cash From Operating Activities -$7.530M -$7.184M
YoY Change 30.78% 42.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.000
YoY Change
NET CHANGE
Cash From Operating Activities -7.530M -7.184M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 3.000
Net Change In Cash -7.530M -7.184M
YoY Change 29.19% 41.69%
FREE CASH FLOW
Cash From Operating Activities -$7.530M -$7.184M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$7.530M -$7.184M
YoY Change 32.41% 41.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2023Q1 dei City Area Code
CityAreaCode
608
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9740507
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9385272
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
97
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30070
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9740507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
1-36598
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11261217
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110125
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
441-8120
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
CY2023Q1 dei Trading Symbol
TradingSymbol
CLRB
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9740507
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12682691
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19866358
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1163745
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
663243
CY2023Q1 us-gaap Assets Current
AssetsCurrent
13846436
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20529601
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
376084
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
546505
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
560334
CY2023Q1 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
63217
CY2022Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
75000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2023Q1 us-gaap Assets
Assets
14838456
CY2022Q4 us-gaap Assets
Assets
21589790
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6904545
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478443
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
51106
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50847
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6955651
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5529290
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
548344
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552981
CY2023Q1 us-gaap Liabilities
Liabilities
7503995
CY2022Q4 us-gaap Liabilities
Liabilities
6082271
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194032651
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193624445
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499043
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7334461
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14838456
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21589790
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6654094
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3887039
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2051207
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2253188
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
8705301
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
6140227
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8705301
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6140227
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
124034
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
430
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124034
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
430
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11261217
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110125
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303805
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
27209162
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408206
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7334461
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42557
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43417
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
408206
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
303805
CY2023Q1 clrb Non Cash Lease Expense
NonCashLeaseExpense
13829
CY2022Q1 clrb Non Cash Lease Expense
NonCashLeaseExpense
21358
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
488719
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107065
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4378
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-32433
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1426102
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
656802
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7183670
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5039783
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30070
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7183667
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5069853
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12682691
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30634122
CY2023Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of March 31, 2023 and December 31, 2022 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of March 31, 2023, and December 31, 2022, uninsured cash balances totaled approximately $12,200,000 and $19,400,000, respectively.</p>
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12200000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
19400000
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8235189
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
732500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
277850
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2366000
CY2023Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
1152000
CY2023Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
832000
CY2023Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
365000
CY2023Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
17000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
14.16
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.31
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.43
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.68
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8304346
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2280962
CY2023Q1 us-gaap Area Of Land
AreaOfLand
3983
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
11800
CY2023Q1 clrb Increase In Percentage Of Rent
IncreaseInPercentageOfRent
0.02
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2018Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
106000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
132000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
147000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
150000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
153000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
207000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
895000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
295000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
600000

Files In Submission

Name View Source Status
0001410578-23-000875-index-headers.html Edgar Link pending
0001410578-23-000875-index.html Edgar Link pending
0001410578-23-000875.txt Edgar Link pending
0001410578-23-000875-xbrl.zip Edgar Link pending
clrb-20230331.xsd Edgar Link pending
clrb-20230331x10q.htm Edgar Link pending
clrb-20230331xex31d1.htm Edgar Link pending
clrb-20230331xex31d2.htm Edgar Link pending
clrb-20230331xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clrb-20230331_cal.xml Edgar Link unprocessable
clrb-20230331_def.xml Edgar Link unprocessable
clrb-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clrb-20230331x10q_htm.xml Edgar Link completed
clrb-20230331_pre.xml Edgar Link unprocessable